Menarini takes over Furiex's PE drug as Janssen fails to perform
This article was originally published in Scrip
Executive Summary
Janssen Pharmaceutica and ALZA (J&J companies) have returned the rights to the premature ejaculation treatment Priligy (dapoxetine) to Furiex Pharmaceuticals. In turn, Furiex has licensed to Menarini rights to commercialise Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Furiex will retain development and commercialisation rights in the US, Japan and Canada.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.